nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2019 | editorial

Overcoming resistance and bypassing checkpoints—possible new therapeutic frontiers in oncology

verfasst von: Andreas Pircher, MD PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Excerpt

The armamentarium of systemic oncological therapies has constantly increased in recent years and in addition to standard chemotherapy now includes targeted therapies, anti-hormonal therapies, anti-angiogenic therapies and immunotherapy. All these therapeutic approaches have been proven a clinical success, often significantly prolonging the lives of cancer patients. However, mostly tumours progress as resistance to these therapies develops biologically, defined by either primary or secondary resistance mechanisms. …

Vorheriger Artikel Obituary for Professor Michael Steurer

Nächster Artikel Saving lives with lung cancer screening

Absenger G. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance. Memo. 2019;12. https://doi.org/10.1007/s12254-019-0488-3.CrossRef

Seeber A, Perathoner A, Kocher F. Resistance in gastrointestinal stromal tumors. Memo. 2019;12. https://doi.org/10.1007/s12254-019-0486-5.CrossRef

Wieser V, Marth C. Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer. Memo. 2019;12. https://doi.org/10.1007/s12254-019-0478-5.CrossRef

Fuereder T. Resistance to immune checkpoint inhibitors. Next steps and combinational approaches. Memo. 2019;12. https://doi.org/10.1007/s12254-019-0493-6.CrossRef

Kaufmann-Guerrero D, Schindler A, Tufman A, Syunyaeva Z, Pfluger T, Huber RM, Berger F, Kahnert K. Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab. Memo. 2019;12. https://doi.org/10.1007/s12254-019-0497-2.CrossRef

Culig Z. Resistance to anti-hormonal therapy in prostate cancer. Memo. 2019;12. https://doi.org/10.1007/s12254-019-0503-8.CrossRef

Titel: Overcoming resistance and bypassing checkpoints—possible new therapeutic frontiers in oncology
verfasst von: Andreas Pircher, MD PhD
Publikationsdatum: 01.06.2019
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-0495-4

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Tobacco control: prevention and cessation in Europe

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab

Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer

Educational no.5: next-generation gene panel sequencing